Pergialiotis Vasilios, Konstantopoulos Panagiotis, Prodromidou Anastasia, Florou Venetia, Papantoniou Nikolaos, Perrea Despina N
Laboratory of Experimental Surgery and Surgical Research N.S. ChristeasAthens University Medical School, Athens, Greece.
Third Department of Obstetrics/GynaecologyAthens University Medical School, Attikon Hospital, Athens, Greece.
Eur J Endocrinol. 2017 Mar;176(3):R159-R166. doi: 10.1530/EJE-16-0611. Epub 2016 Dec 22.
Subclinical hypothyroidism (SCH) is encountered in 10-25% of women with PCOS. To date, it remains unclear whether this coexistence influences the severity of metabolic and hormonal profile of these patients. The purpose of our systematic review is to investigate this potential relation.
We systematically searched Medline, Scopus, ClinicalTrials.gov, Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar databases together with reference lists from included studies. All prospective and retrospective observational cohort studies that investigated the impact of subclinical hypothyroidism on hormonal and metabolic parameters of PCOS patients were included. The methodological quality of studies was assessed with the Ottawa-Newcastle criteria. Statistical meta-analysis was performed with the RevMan 5.3 software.
Twelve studies were finally included in the present review, which enrolled 2341 PCOS patients. Among them, 577 had subclinical hypothyroidism, whereas the remaining 2077 were PCOS women with normal thyroid function. The presence of SCH significantly affected HDL (MD -3.92 mg/dL 95% CI: -6.56, -1.29) and triglycerides levels (26.91 mg/dL 95% CI: -3.79, 50.02). HOMA-IR was also affected (MD 0.82 95% CI: 0.15, 1.50). On the other hand, LDL, fasting glucose and 2-h OGTT were not influenced. Similarly, prolactin, FSH, LH, LH/FSH ratio and sex hormone-binding globulin remained unaffected.
Subclinical hypothyroidism does not influence the hormonal profile of women with PCOS. On the other hand, it results in mild metabolic abnormalities, which are not clinically important in a short-term setting.
10%至25%的多囊卵巢综合征(PCOS)女性存在亚临床甲状腺功能减退(SCH)。迄今为止,这种共存情况是否会影响这些患者的代谢和激素状况的严重程度仍不清楚。我们进行系统评价的目的是研究这种潜在关系。
我们系统检索了Medline、Scopus、ClinicalTrials.gov、Cochrane对照试验中心注册库(CENTRAL)和谷歌学术数据库以及纳入研究的参考文献列表。纳入所有调查亚临床甲状腺功能减退对PCOS患者激素和代谢参数影响的前瞻性和回顾性观察队列研究。采用渥太华-纽卡斯尔标准评估研究的方法学质量。使用RevMan 5.3软件进行统计荟萃分析。
本综述最终纳入12项研究,共纳入2341例PCOS患者。其中,577例有亚临床甲状腺功能减退,其余2077例为甲状腺功能正常的PCOS女性。SCH的存在显著影响高密度脂蛋白(MD -3.92mg/dL,95%CI:-6.56,-1.29)和甘油三酯水平(26.91mg/dL,95%CI:-3.79,50.02)。胰岛素抵抗指数(HOMA-IR)也受到影响(MD 0.82,95%CI:0.15,1.50)。另一方面,低密度脂蛋白、空腹血糖和2小时口服葡萄糖耐量试验不受影响。同样,催乳素、促卵泡生成素(FSH)、促黄体生成素(LH)、LH/FSH比值和性激素结合球蛋白也未受影响。
亚临床甲状腺功能减退不影响PCOS女性的激素状况。另一方面,它会导致轻度代谢异常,在短期内这些异常在临床上并不重要。